ETC-216

From Aaushi
Jump to navigation Jump to search
[1]

Introduction

Mutant form of HDL with point mutation apolipoprotein A1. Occurs in a small community in northern Italy with long-lived individuals. ETC-216 (recombinant mutant apo A1) injected intravenously, found to reduce size of atheromatous plaques.

More general terms

References

  1. ↑ Journal Watch 23(24):189, 2003
    Nissen SE et al Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290:2292, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/14600188
Retrieved from "https://aaushi.info/w/index.php?title=A5720&oldid=917391"